<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082419</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2009/21</org_study_id>
    <nct_id>NCT01082419</nct_id>
  </id_info>
  <brief_title>Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity</brief_title>
  <acronym>NARFI</acronym>
  <official_title>Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity - Norms in ARFI: Distribution and Reproducibility of ARFI Values in Disease-free Livers or Pathological Livers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver stiffness measurement (LSM) by non invasive methods is increasingly used to estimate
      liver fibrosis in patients with chronic liver diseases. However, there is growing evidence
      that fibrosis is not the only determinant of liver stiffness. Indeed inflammation,
      cholestasis, congestion could also interfere with stiffness measurements. Acoustic radiation
      force impulse imaging (ARFI) is a new technology to perform real time LSM. Using a standard
      ultrasonographic probe, it offers elastography with a flexible metering box at variable
      depth, allowing the examination of specific area.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are many causes of chronic liver diseases such as hepatitis C infection, hepatitis B
      infection, alcohol, NAFLD (non-alcoholic fatty liver disease), drugs and auto-immune liver
      disease.

      Although the causes differ the pathological response to injury tends to be similar leading to
      fibrosis and cirrhosis.

      Liver biopsy is the current gold standard for the assessment of liver fibrosis but is poorly
      suited for active monitoring because of its expense and morbidity. Thus, development of
      alternatives that are safe, inexpensive, and reliable is a priority.

      Liver stiffness measurement (LSM) by non invasive method is increasingly used to estimate
      liver fibrosis in patient with chronic liver disease. Acoustic radiation force impulse
      imaging (ARFI) is a new technology to perform real time LSM. Using a standard
      ultrasonographic probe, it offers elastography with a flexible metering box at variable
      depth, allowing the examination of specific area.

      The purpose of this work was to evaluate by ARFI, the efficiency of this new technique, the
      reproducibility inter and intra observer, and the liver elasticity obtained by this method in
      different patient groups.

      The primary endpoint of this work is to evaluate by ARFI, the efficiency of the technique,
      the reproducibility inter and intra observer, and the elasticity of liver in 6 different
      patient groups and healthy volunteers.

      The different population groups are:

        -  healthy volunteers Group A

        -  patients with supposed disease free liver (normal hepatic and pancreatic biochemistry).
           Group B

        -  patients with non cirrhotic hepatopathy. Group C

        -  patients with cirrhosis. Group D

        -  patients with liver tumour and surgery indication. Group E

        -  patients with reversible liver diseases:

             -  patients with acute left cardiac insufficiency. Group F

             -  patients with biliary cholestasis. Group G

      ARFI measurements will be performed in a single liver ultrasound exam visit except for
      patients with reversible liver diseases who will have a second visit with ARFI measurement
      after clinical healing. The ARFI values are expressed as a speed in m/s.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.</measure>
    <time_frame>One or two 30 min visit according to the patient group</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter and intra observer reproducibility</measure>
    <time_frame>Three 30 min visits in healthy volunteer group.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease</measure>
    <time_frame>From patient admission until patient healing in groups F&amp;G.</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Viral Hepatitis</condition>
  <condition>Liver Tumour</condition>
  <condition>Cardiac Failure</condition>
  <condition>Biliary Cholestasis.</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with liver tumour and surgery indication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with reversible liver diseases and with acute left cardiac insufficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with non cirrhotic hepatopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with reversible liver diseases and with biliary cholestasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARFI measurement</intervention_name>
    <description>ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a &quot;light&quot; apnea.
For group A the measurement is made by a second and a third investigator during the same examination.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARFI measurement</intervention_name>
    <description>ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a &quot;light&quot; apnea.
For all other groups (B, C, D, E) ARFI is measured only once.</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARFI measurement</intervention_name>
    <description>ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a &quot;light&quot; apnea.
For groups F and G : ARFI is measured again after clinical healing.</description>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or Woman

          -  Age&gt; 18 years old

          -  Able to understand the study and to give informed consent

          -  Informed consent signed by patient and investigator before any study required
             examination

          -  With a valid health insurance

          -  Groups specific inclusion criteria are:

          -  Group A : healthy volunteers without known liver disease

          -  Group B : voluntary patients without known liver disease

          -  Group C and D Patient with a diagnosed chronic liver disease

          -  Group E : patients with liver tumors (benign or malignant) with surgical indication

          -  Group F : patients with acute right heart insufficiency diagnosed by a cardiologist

          -  Group G :patients with biliary cholestasis and imaging evidence of biliary dilatation

        Exclusion Criteria:

          -  Patient under 18 years old

          -  Not able to understand the study or to give their consent.

          -  Pregnant woman

          -  Severe respiratory insufficiency

          -  Unable to perform a &quot;light&quot; apnea .

          -  hemodynamic instability (cardiogenic shock, septic or anaphylactic) possibility of
             disruption of the elasticity and inability to carry patient.

          -  Chronic heart insufficiency.

          -  deprived of their liberty by court
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora FRULIO, Md MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adela√Øde Doussau, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol. 2009 Jan;50(1):17-35. doi: 10.1016/j.jhep.2008.10.016. Epub 2008 Nov 8. Review.</citation>
    <PMID>19022517</PMID>
  </reference>
  <reference>
    <citation>Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008 May;48(5):835-47. doi: 10.1016/j.jhep.2008.02.008. Epub 2008 Feb 26. Review.</citation>
    <PMID>18334275</PMID>
  </reference>
  <reference>
    <citation>Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034. Epub 2008 Jan 18. Review.</citation>
    <PMID>18395077</PMID>
  </reference>
  <reference>
    <citation>Ferraioli G, Gulizia R, Filice C. Real-time elastography in the assessment of liver fibrosis. AJR Am J Roentgenol. 2007 Sep;189(3):W170.</citation>
    <PMID>17715090</PMID>
  </reference>
  <reference>
    <citation>Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol. 2007 Mar;188(3):758-64.</citation>
    <PMID>17312065</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver stiffness measurement</keyword>
  <keyword>ARFI</keyword>
  <keyword>fibrosis</keyword>
  <keyword>hepatopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

